Taro Pharmaceutical Industries (TARO) Financials
Stock symbol TARO is outdated, potentially delisted? Maybe it is available on other exchange?
TARO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2023 | 2.2 billion | 384.1 million |
| Sept. 30, 2023 | 2.1 billion | 371.9 million |
| June 30, 2023 | 2.1 billion | 396.5 million |
| March 31, 2023 | 2.1 billion | 404.7 million |
TARO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2023 | -3.6 million | ? |
| Sept. 30, 2023 | 40.5 million | ? |
| June 30, 2023 | 933000 | ? |
| March 31, 2023 | 48.1 million | ? |
TARO Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| Dec. 31, 2023 | 20.2 million |
| Sept. 30, 2023 | 8.5 million |
| June 30, 2023 | 10.0 million |
| March 31, 2023 | 6.9 million |
TARO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2023 | 902.2 million | - | - |
| Sept. 30, 2023 | 907.0 million | - | - |
| June 30, 2023 | 806.2 million | - | - |
| March 31, 2023 | 850.3 million | - | 2.0 million |
TARO Shares Outstanding
TARO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2023 | 34.5 million | 13.6 million | 50.4 million | - |
| Sept. 30, 2023 | 7.0 million | 14.3 million | 54.5 million | - |
| June 30, 2023 | 6.8 million | 16.1 million | 55.9 million | - |
| March 31, 2023 | 8.5 million | 16.3 million | 35.6 million | 14.5 million |
TARO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2023 | 157.1 million | 77.3 million |
| Sept. 30, 2023 | 148.2 million | 74.6 million |
| June 30, 2023 | 158.9 million | 94.8 million |
| March 31, 2023 | 146.6 million | 70.9 million |
TARO
Price: $42.98
52 week price:
Earnings Per Share: 1.43 USD
P/E Ratio: 29.90
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Israel
Volume: 10328
Ebitda: 458.4 millionMarket Capitalization: 1.6 billion